tiprankstipranks
Advertisement
Advertisement

NKTR Stock Latest News

Citi opens ‘upside 30-day catalyst watch’ on Nektar into data
The FlyCiti opens ‘upside 30-day catalyst watch’ on Nektar into data
10d ago
NKTR
Nektar Therapeutics: Buy Rating on Favorable Alopecia Areata Rezpeg Data Outlook and 30‑Day Catalyst Upside Potential
PremiumRatings
Nektar Therapeutics: Buy Rating on Favorable Alopecia Areata Rezpeg Data Outlook and 30‑Day Catalyst Upside Potential
10d ago
NKTR
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline
PremiumClass Action
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline
14d ago
NKTR
Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies
PremiumThe Fly
Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies
19d ago
NKTR
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Trial Protocol Violations: Levi & Korsinsky
PremiumClass Action
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Trial Protocol Violations: Levi & Korsinsky
22d ago
NKTR
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures
PremiumClass ActionNektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures
24d ago
NKTR
Nektar initiated with a Neutral at Wedbush
Premium
The Fly
Nektar initiated with a Neutral at Wedbush
24d ago
NKTR
Nektar management to meet with BTIG
Premium
The Fly
Nektar management to meet with BTIG
25d ago
NKTR
DraftKings, Eli Lilly downgraded: Wall Street’s top analyst calls
PremiumThe Fly
DraftKings, Eli Lilly downgraded: Wall Street’s top analyst calls
1M ago
LI
AJG
Nektar Therapeutics: Rezpeg Clinical Momentum and Strong Cash Runway Underscore Attractive Risk‑Reward at Current Levels
PremiumRatings
Nektar Therapeutics: Rezpeg Clinical Momentum and Strong Cash Runway Underscore Attractive Risk‑Reward at Current Levels
1M ago
NKTR
Nektar initiated with a Buy at TD Cowen
PremiumThe Fly
Nektar initiated with a Buy at TD Cowen
1M ago
NKTR
Buy Rating on Nektar Driven by Rezpeg’s Blockbuster Potential in Atopic Dermatitis and Alopecia Areata
PremiumRatings
Buy Rating on Nektar Driven by Rezpeg’s Blockbuster Potential in Atopic Dermatitis and Alopecia Areata
1M ago
NKTR
Nektar price target raised to $123 from $102 at Citi
PremiumThe FlyNektar price target raised to $123 from $102 at Citi
1M ago
NKTR
Nektar Therapeutics Bets Big on Respag Phase 3
Premium
Company Announcements
Nektar Therapeutics Bets Big on Respag Phase 3
1M ago
NKTR
Nektar price target raised to $140 from $115 at Oppenheimer
Premium
The Fly
Nektar price target raised to $140 from $115 at Oppenheimer
1M ago
NKTR
Morning Movers: Adobe falls with Narayen set to exit as CEO
PremiumThe Fly
Morning Movers: Adobe falls with Narayen set to exit as CEO
1M ago
KLC
NIO
Closing Bell Movers: Adobe down 8% despite Q1 beat as CEO steps down
PremiumThe Fly
Closing Bell Movers: Adobe down 8% despite Q1 beat as CEO steps down
1M ago
S
LEN
Nektar reports Q4 EPS ($1.78) vs. 52c last year
PremiumThe Fly
Nektar reports Q4 EPS ($1.78) vs. 52c last year
1M ago
NKTR
Nektar options imply 5.9% move in share price post-earnings
PremiumThe Fly
Nektar options imply 5.9% move in share price post-earnings
1M ago
NKTR
NKTR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsNKTR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
NKTR
Nektar price target raised to $150 from $105 at B. Riley
Premium
The Fly
Nektar price target raised to $150 from $105 at B. Riley
2M ago
NKTR
Nektar enters research collaboration for NKTR-0165 in multiple sclerosis
Premium
The Fly
Nektar enters research collaboration for NKTR-0165 in multiple sclerosis
2M ago
NKTR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >